Exousia Pro为该联合会的超强科技提供了全球许可证,从而得以进行基于唾液的早期癌症测试。 Exousia Pro secures global license for UCF’s exosome tech, enabling a saliva-based early cancer test.

Exousia Pro, Inc. 与中佛罗里达州大学最后敲定了一项全球独家许可证协议,涉及专利外观技术,包括利用异种NANOGDNA进行唾液测试,以早期检测多种癌症类型。 Exousia Pro, Inc. has finalized an exclusive global licensing deal with the University of Central Florida for patented exosome-based technologies, including a saliva test using exosomal NANOG DNA to detect multiple cancer types early. 非侵入性试验仅需要2毫升的唾液,并使用PCR,目的是以高精确度确定具有攻击性、难以检测的癌症。 The non-invasive test, requiring only 2 ml of saliva and using PCR, aims to identify aggressive, hard-to-detect cancers with high accuracy. 该公司计划推出 " Exousia Health " ,将诊断工具商业化,并将其子公司LAMY重新命名为 " Exousia Bio, Inc. " ,重点关注基于外观的疗法。 The company plans to launch Exousia Health to commercialize the diagnostic tool and rebrand its subsidiary LAMY as Exousia Bio, Inc. to focus on exosome-based therapies. 该协议标志着液体生物检查和定向治疗开发方面的一项关键进展。 The agreement marks a key advancement in liquid biopsy and targeted treatment development.